Product information and disease descriptionPlace of product in therapyDisease description
Diagnosis
10 evidence topics · 8 sources
Clinical diagnosis and confirmatory testing
“The diagnosis of autoimmune Myasthenia Gravis (MG) remains clinical and rests on the history and physical findings of fatigable, fluctuating muscle weakness in a specific distribution.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ancillary bedside tests and laboratory methods help confirm the synaptic disorder, define its type and severity, classify MG according to the causative antibodies, and assess the effect of treatment objectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Diagnosis is straightforward in most patients with typical symptoms and a positive antibody test, although a detailed clinical and neurophysiological examination is important in antibody-negative patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Antibody testing: AChR antibodies
“In a patient with clinical features of MG, serum testing for AChR-Ab is the first recommended step in diagnosis by most recent guidelines and expert opinions” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The test has a very high specificity, so the detection of elevated titers in the appropriate clinical setting is diagnostic of AChR-myasthenia, and further testing may not be necessary” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The RIPA for binding Ab is abnormal in up to 85% of adult patients with generalized MG, but only about 50% of patients with ocular MG” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The technique detects autoantibodies to clustered AChR in about 15% of RIPA-seronegative MG patients” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antibody testing: MuSK and LRP4 antibodies and seronegative disease
“MuSK-Ab are found in about 6–8% of all MG cases” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In approximately 15% of patients with generalized MG and 50% of patients with ocular MG, both AChR and MuSK antibodies were absent.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Detection rates in double-seronegative patients range from 2% to 50%, depending on the geographical origin, with LRP4-Ab being more frequent in non-Caucasian patients, and on the employed assay, with Live CBA being the most widely used” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antibody testing: United States testing patterns after a new diagnosis
“Of 5788 cases, 2590 (44.7 %) had at least one valid serology test result: 1453 (56.3 %) seronegative, 1094 (42.4 %) anti-AChR+, 28 (1.1 %) anti-MuSK+, and 5 (0.2 %) anti-LRP4+.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among the seronegative, 56.6 % were only tested for anti-AChR antibodies, 33.7 % tested both anti-AChR and anti-MuSK antibodies, and 5.0 % tested all three antibodies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Electrodiagnosis: repetitive nerve stimulation
“In generalized MG, RNS of distal muscles is abnormal in 30–35% of patients, while in proximal muscles, it is abnormal 60–70%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One should note as a standard feature the high specificity of RNS, which reaches about 97% in generalized MG and 94% in ocular MG” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Electrodiagnosis: single-fiber and concentric needle jitter
“The jitter study is the most sensitive indicator of impaired neuromuscular transmission” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The CNE jitter is abnormal in 98–100% in generalized MG and above 90% in ocular MG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While highest in sensitivity, jitter measurements are not specific and may be abnormal in other synaptic disorders, in denervation and reinnervation processes (poly- and mononeuropathies), some myopathies, and with motor neuron disorder (MND) in particular” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bedside tests: ice-pack and edrophonium tests
“The test is used mostly in ocular MG and seems more popular among neuro-ophthalmologists; some authors report sensitivities equal to that of single-fiber electromyography (SFEMG) in patients presenting with ptosis and a very high negative predictive value” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, others note much lower specificity at about 25%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the USA, edrophonium has been discontinued since 2018” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MGFA clinical classification
Consensus definitions: treatment goal, remission, crisis, and refractory disease
“MMS: The patient has no symptoms or functional limitations from MG but has some weakness on examination of some muscles.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Rapid clinical worsening of MG that, in the opinion of the treating physician, could lead to crisis in the short term (days to weeks).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Worsening of myasthenic weakness requiring intubation or noninvasive ventilation to avoid intubation, except when these measures are employed during routine postoperative management” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PIS3 is unchanged or worse after corticosteroids and at least 2 other IS agents, used in adequate doses for an adequate duration, with persistent symptoms or side effects that limit functioning, as defined by patient and physician.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnostic delay: United States patients with generalized myasthenia gravis
“Quantitative surveys and qualitative interviews were conducted (January-May 2023) in patients with gMG (n = 71 surveys; n = 47 interviews) and clinicians in the United States treating patients with gMG (n = 12 surveys and interviews).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients had mean (SD) diagnostic journey time of 11.8 (22.5) months from symptom onset to seeking care and 15.5 (36.7) months from seeking care to diagnosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Sources of diagnostic journey delay (≥9.9 % patients) were: clinicians mistaking gMG symptoms as female health issues, difficulty accessing specialty care, and lack of gMG knowledge among HCPs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote